TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens

McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N Engl J Med, 334, 1, 10.1056/NEJM199601043340101

Ozols, 1997, Chemotherapy of advanced ovarian cancer: current status and future directions, Semin Oncol, 24

Schiff, 1979, Promotion of microtubule assembly in vitro by taxol, Nature, 277, 665, 10.1038/277665a0

Dumontet, 1999, Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death, J Clin Oncol, 17, 1061, 10.1200/JCO.1999.17.3.1061

Fang, 1998, “Loop” domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis, Cancer Res, 58, 3202

Makhija, 1999, Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids, Int J Oncol, 14, 515

Shitashige, 2001, Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2, J Biochem, 130, 741, 10.1093/oxfordjournals.jbchem.a003044

Jones, 1998, Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53, Mol Pharmacol, 53, 819

Giannakakou, 1997, Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization, J Biol Chem, 272, 17118, 10.1074/jbc.272.27.17118

Gonzalez-Garay, 1999, A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance, J Biol Chem, 274, 23875, 10.1074/jbc.274.34.23875

Kavallaris, 1997, Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes, J Clin Invest, 100, 1282, 10.1172/JCI119642

Ferlini, 2005, The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance, Cancer Res, 65, 2397, 10.1158/0008-5472.CAN-04-3065

Ciardiello, 2002, ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells, Int J Cancer, 98, 463, 10.1002/ijc.10230

Boudny, 2002, Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2, Br J Cancer, 86, 463, 10.1038/sj.bjc.6600080

Ferlini, 2003, Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance, Mol Pharmacol, 64, 51, 10.1124/mol.64.1.51

Poruchynsky, 2001, Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism, Biochem Pharmacol, 62, 1469, 10.1016/S0006-2952(01)00804-8

Strobel, 1996, BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway, Proc Natl Acad Sci U S A, 93, 14094, 10.1073/pnas.93.24.14094

De Feudis, 2000, Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis, Neoplasia, 2, 202, 10.1038/sj.neo.7900086

Tsuruta, 2001, Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines, Eur J Cancer, 37, 531, 10.1016/S0959-8049(00)00431-7

Tai, 1998, BAX protein expression and clinical outcome in epithelial ovarian cancer, J Clin Oncol, 16, 2583, 10.1200/JCO.1998.16.8.2583

Protopapas, 2004, The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy, Eur J Gynaecol Oncol, 25, 225

Palmer, 2008, P53 and blc-2 assessment in serous ovarian carcinoma, Int J Gynecol Cancer, 18, 241, 10.1111/j.1525-1438.2007.01000.x

De la Torre, 2007, Apoptosis in epithelial ovarian tumours. Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax), Eur J Obstet Gynecol Reprod Biol, 130, 121, 10.1016/j.ejogrb.2005.11.048

Geisler, 2000, p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months, Gynecol Oncol, 77, 278, 10.1006/gyno.2000.5780

Malamou-Mitsi, 2007, Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer, Anticancer Res, 27, 1157

Smith-Sorensen, 1998, Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status, Br J Cancer, 78, 375, 10.1038/bjc.1998.502

Lavarino, 2000, p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma, J Clin Oncol, 18, 3936, 10.1200/JCO.2000.18.23.3936

Ueno, 2006, Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin, Cancer Lett, 241, 289, 10.1016/j.canlet.2005.10.035

Kupryjanczyk, 2008, TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study, BMC Cancer., 8, 27, 10.1186/1471-2407-8-27

Kupryjanczyk, 2003, Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen, Br J Cancer, 88, 848, 10.1038/sj.bjc.6600789

2003

Creasman, 1989, Announcement, FIGO stages 1988, revisions, Gynecol Oncol, 35, 125

Christian, 1994, Salvage chemotherapy for epithelial ovarian carcinoma, Gynecol Oncol, S143, 10.1006/gyno.1994.1354

Dansonka-Mieszkowska, 2006, Geographical variations in TP53 mutational spectrum in ovarian carcinomas, Ann Hum Genet, 70, 594, 10.1111/j.1469-1809.2006.00257.x

Marx, 1997, Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer, Anticancer Res, 17, 2233

Rogers, 2002, Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo, Int J Cancer, 97, 858, 10.1002/ijc.10132

Blagosklonny, 2001, Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death?, Bioessays, 23, 947, 10.1002/bies.1135

Spentzos, 2005, Unique gene expression profile based on pathologic response in epithelial ovarian cancer, J Clin Oncol, 23, 7911, 10.1200/JCO.2005.02.9363

Cannistra, 2000, When is a “prognostic factor” really prognostic?, J Clin Oncol., 18, 3745, 10.1200/JCO.2000.18.22.3745

Kupryjanczyk, 2006, Why TP53 status does not associate with clinical endpoints in ovarian cancer: facts and hypotheses, Gynecol Oncol, 100, 5, 10.1016/j.ygyno.2005.08.003

Goncalves, 2001, Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics, Proc Natl Acad Sci USA, 98, 11737, 10.1073/pnas.191388598

Carles, 1999, Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs, Br J Cancer, 80, 1162, 10.1038/sj.bjc.6690481

Xia, 2006, Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis, Leukemia, 20, 1009, 10.1038/sj.leu.2404198

Shakuto, 2006, Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice, Gan To Kagaku Ryoho, 33, 337

Eisenhauer, 2007, Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum-taxane chemotherapy, Gynecol Oncol, 106, 381, 10.1016/j.ygyno.2007.04.012

Bicher, 1993, Age does not influence taxol dose intensity in recurrent carcinoma of the ovary, Cancer, 71, 594, 10.1002/cncr.2820710216